Protara Therapeutics (TARA) Non Operating Income (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Non Operating Income data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 16.43% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 12.23% increase from a year earlier, with the FY2025 full-year figure at $7.1 million, up 55.99% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.8 million, up from $1.8 million in the prior quarter.
• Over the last five years, Non Operating Income for TARA reached as high as $2.2 million in Q1 2025 and fell as low as $119000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $1.0 million across 5 years, with a median of $846000.0 in 2023.
• Across the five-year window, Non Operating Income jumped 1560.0% in 2022 and dropped 16.43% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $542000.0 in 2022, then jumped by 51.29% to $820000.0 in 2023, then jumped by 88.17% to $1.5 million in 2024, then grew by 14.84% to $1.8 million in 2025, then increased by 4.23% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $1.5 million in Q3 2025.